NEXT Life Sciences is a medical device company that plans to deliver the first male contraceptive solution that is non-hormonal, long lasting, and reversible.

Particular Ventures

StartUp Health

NEXT Life Sciences, Inc.

In addition to NBC News coverage last week, we also had Arizona's Family CBS News tour our Flagstaff lab with our Chief Science Officer, Robert S. Kellar, Ph.D., where he and the team are hard at work optimizing and testing Plan A™!

Dr. Kellar shared, “Having the ability to develop new technology that gives not just men but partners, couples, some other options to consider in family planning is a really big deal.” With that importance being highlighted by our CEO L.R. Fox as "[enabling] people to proactively plan when they’re going to get pregnant.” 

We were also excited to see this news featured on Microsoft Start! You can catch the coverage at the link here: https://buff.ly/3JhDoqO

This week, 12 News (KPNX-TV, NBC) Arizona visited our Flagstaff lab with our Chief Science Officer, Robert S. Kellar, Ph.D., for an in-person look at Plan A™ and interviewed our CEO L.R. Fox about the skyrocketing interest we're seeing in male birth control!

Catch the coverage in full here: https://buff.ly/3Q2gqro

Birth control has disproportionately fallen on women... but now male contraception is in demand. In this week's Future Pulse from POLITICO, Ruth Reader sat down with our CEO L.R. Fox to chat about Plan A™ and the future of male contraception.

Read the interview on POLITICO here: https://buff.ly/3TMzqv4

Our CEO L.R. Fox sat down this week with Will Pavia from The Times for a closer look at his journey as an entrepreneur and to share more about his vision for Plan A & the future of #malebirthcontrol 

You can read the full article on The Times here: https://buff.ly/3PFyffM!

Have you ever wondered what it looks like in the labs where our leading scientists are making breakthroughs in male contraception? 

Melissa Sevigny, a reporter with KNAU, Arizona’s NPR affiliate, toured our Flagstaff lab where we’re working on Plan A, the reversible, long-lasting birth control for men:

“The goal is ten years of protection with one injection, reversible at any time with a second injection that dissolves the material and flushes it out. It’s called a LARC – Long Acting, Reversible Contraception. NEXT Life says it’s the holy grail of birth control.

L.R. Fox, the NEXT Life Sciences, Inc. CEO, sees a desperate need for products like Plan A, which he intends to bring to human clinical trials within the year. ‘The human right to choose when and if to have a child, is so fundamental, and yet is lacking in every single country, even the most industrialized countries in the world,’ Fox says.

For him, this issue is personal. ‘Coming from foster care myself, seeing the devastating impact of unplanned pregnancies, I chose to get a vasectomy,’ Fox says. ‘It’s a burden that I carry every day, knowing that I might not be able to ever have a child, because Plan A didn’t exist and wasn’t an option for me.’

And there are plenty of signs that Fox isn’t alone in wanting more choices. Though Plan A isn’t yet on the market, fifty thousand people have signed up for the interest list.”

Give the full piece a listen here: https://buff.ly/3PyASjA 

And learn more about the future of family planning here: PlanAforMen.com

We are extremely grateful and excited to announce that NEXT Life Sciences, Inc. has entered into a partnership with Male Contraceptive Initiative to receive a grant of $400K to support clinical trial research toward Plan A™!

Male Contraceptive Initiative (MCI), is the largest 501(c)(3) non-profit in the world dedicated to advancing male contraception. They accomplish their vision, “Reproduction Autonomy for All”, by bringing new male contraceptives to market through direct funding, technical support, research, and advocacy. This investment from MCI will help accelerate our team's progress toward giving men equitable access to participate in family planning with an option like Plan A™.

MCI Executive Director Heather Vahdat, MPH, shared: “The number of men and their partners expressing the desire for male contraceptive options continues to increase, and part of MCI’s dedication to accelerating product development includes thinking proactively about how to ensure a variety of delivery options. We are pleased to be able to get behind the talent and energy of NEXT Life Sciences in order to achieve a real vision for a shared contraceptive future.”

You can read more about this grant and our partnership in the article on AP News here: https://buff.ly/49BLNB8

IPhone / Mobile Compatible

Viewport Meta

SSL by Default

Google Tag Manager

HSTS

Google Analytics

Content Delivery Network

Global Site Tag

LetsEncrypt

Google Analytics 4

Founder & Chairman

Luke Fox

Marketing Director

Blake Lopez

Chief of Staff

Gracie Blaising

Chuck Carignan

Chief Medical Officer

Cindy Domecus

Chief Regulatory Advisor

Western US Biotechnology Companies

Western US Startups Founded in 2021

California Medical Companies with Seed Funding

Biotechnology Companies With Fewer Than 50 Employees (Top 10K)

NEXT Life Sciences is developing the revolutionary Plan A™ procedure to bring the only scientifically proven technology in the category - Vasalgel® - to market.

Seed Round - NEXT Life Sciences

Venture Round - NEXT Life Sciences

San Luis Obispo

California

United States

North America

NEXT Life Sciences

The Family Leads NEXT Life Sciences $2.5 Million Funding Round for Plan A Male Birth Control

NEXT Life Sciences Secures $2.5M in Funding to Advance Male Contraceptive Product Plan A

Bolt's Ryan Breslow Is Backing This Male Birth Control Startup

Male birth control maker raises $2.5 million to develop “Plan A”

NEXT Life Sciences Secures $2.5M for ‘Plan A’ Male Birth Control

A non-hormonal, reversible procedure utilizing Vasalgel® technology.

Morocco

Africa

Philippines

Asia

Imperial Life Sciences is a competitor of NextLife Sciences specializing in innovative medical devices and technologies for healthcare.

Imperial Life Sciences

SCIREQ Scientific Respiratory Equipment competes with NextLife Sciences in the development of advanced medical devices and technologies for respiratory care.

SCIREQ Scientific Respiratory Equipment

Brainsway is a competitor of NextLife Sciences, specializing in innovative medical devices and technologies for neurological and psychiatric applications.

Brainsway

LUMICKS competes with NextLife Sciences in the development of cutting-edge medical devices and technologies for life science research and applications.

LUMICKS

NextLife Sciences, Inc. is a company that specializes in the development of innovative medical devices and technologies aimed at improving healthcare outcomes. Their focus is on creating solutions that address unmet clinical needs in various medical fields.

news impact assignment basic	general	May 13, 2024 4:26 PM	ac8ad26e
public peers	general	May 12, 2024 3:08 AM	f19f9977
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	May 13, 2024 3:05 AM	1f624a9a
company summary	general
signals	general
crunchbase trigger	general	Dec 4, 2024 8:54 AM	f3339a4f
crunchbase profile	general	Dec 4, 2024 12:36 PM	28a4d295
li profile	general	May 12, 2024 3:08 AM	b98fae36
translate crunchbase fundingrounds	general	Dec 4, 2024 1:36 PM	9daf07bd
peers	general
news basic	general	May 12, 2024 3:08 AM	fd02d49a
bundesanzeiger	filings
financials download nd	financials
private financials	financials

ORG:NEXTLIFESCIENCES

NextLife Sciences, Inc.